Sustained response in early responders to safinamide in patients with Parkinson's disease and motor fluctuations: A post hoc analysis of the SETTLE study

Safinamide is a selective, reversible, monoamine oxidase B inhibitor for the treatment of patients with Parkinson's disease (PD) and motor fluctuations. This was a post hoc analysis of the SETTLE study, in which patients with PD and motor fluctuations were randomly assigned to 24-week treatment with safinamide (50 mg/day for 2 weeks, increased to 100 mg/day if tolerated) or placebo. In the present analysis, responders were defined according to their treatment responses at Week 2 and Week 24 based on changes in ON-time without troublesome dyskinesia from baseline with cutoffs of 1 hour. It was found that 81% (103/127) of the responders at Week 2 maintained the response through Week 24 in the safinamide group. Other outcomes did not necessarily coincide with the ON-time response; however, “Early” responders who showed a treatment response at both Week 2 and Week 24 had substantial improvements from baseline in OFF-time, UPDRS Part II and III scores, and PDQ-39 summary index scores through Week 24. The safinamide group had a higher proportion of early responders than the placebo group (39% vs 20%, p < 0.0001). At baseline, early responders in the safinamide group had significantly higher UPDRS Part II and III scores, shorter ON-time, and longer OFF-time than the other responder populations. In conclusion, the results of the present post hoc analysis suggest that patients with a short ON-time, severe motor symptoms, and highly compromised activities of daily living can benefit from safinamide early in treatment and over the long term

Application of the binary interaction approximation to plasma oscillation

The BIA (Binary Interaction Approximation) formulation in the presence of neutralizing immovable background ion is presented for analysis of multiple electron motion. Such a BIA scheme is applied to electrons in plasmas. A test calculation shows that 1) the plasma oscillation and its frequency are successfully detected, 2) the CPU time for the BIA are less than 1.5 sec and 1 hour for two and three dimensional analysis, while 127 sec and 13 hours for the direct integration method (DIM) by using a Runge-Kutta-Fehlberg integrator with an absolute error tolerance of 10−16, and 3) the number of time steps for the DIM, in such a case, are as many as 5.8 × 104 and 3.6 × 106, while those for the BIA are only 256 and 512.This article is based on the presentation at the 21st International Toki Conference (ITC21

Accuracy assurance in binary interaction approximation for N-Body problems

Two accuracy assurance schemes are combined into the Binary Interaction Approximation (BIA) to N-body problems. The first one is a sort of variable time step (VTS) scheme for a given error tolerance. Since this scheme sometimes does not converge, an error-tolerance-adjusting (ETA) scheme is also introduced. With these two schemes combined into the original BIA, a significant improvement in terms of numerical error is obtained.This article is based on the presentation at the 21st International Toki Conference (ITC21

Molecular cytogenetics of Lycopersicon Mill

SIGLEAvailable from British Library Document Supply Centre-DSC:DXN032670 / BLDSC - British Library Document Supply CentreGBUnited Kingdo

Accuracy Assurance in Binary Interaction Approximation for N-Body Problems

Two accuracy assurance schemes are combined into the Binary Interaction Approximation (BIA) to N-body problems. The first one is a sort of variable time step (VTS) scheme for a given error tolerance. Since this scheme sometimes does not converge, an error-tolerance-adjusting (ETA) scheme is also introduced. With these two schemes combined into the original BIA, a significant improvement in terms of numerical error is obtained.This article is based on the presentation at the 21st International Toki Conference (ITC21

Real‐world treatment patterns of patients with atopic dermatitis in Japan: Analysis of the JMDC Claims Database

Abstract Objectives This study was conducted to assess changes in the real‐world treatment of atopic dermatitis (AD) in Japan. Methods Patients from the JMDC Claims Database with ≥1 confirmed diagnosis of AD, an identifiable medical care start date for AD, and ≥2 AD–related treatments on separate dates between January 1, 2005, and May 31, 2019, were included; data were analyzed on a yearly basis. Results In total, 411,102 patients were included. The average age of patients increased from 12.0 to 18.8 years between 2005 and 2017. In any given year, the prevalence of AD was highest in patients aged <2 years and lowest in patients aged ≥50 years. Dermatology (65.1%‐69.5% from 2005 to 2017) and clinics (92.3%‐93.4%) were the main department and medical facility, respectively, providing daily medical care for AD. The proportion of patients who were given the thymus and activation‐regulated chemokine test increased from 2008 to 2017 (0.03%‐3.5%). From 2005 to 2017, the proportion of patients who received moisturizer (68.8%‐79.1%), topical calcineurin inhibitors (8.2%‐17.8%), very strong topical corticosteroids (26.0%‐40.6%), strongest topical corticosteroids (3.5%‐7.8%), cyclosporine (0.01%‐0.3%), or phototherapy (0.06%‐1.8%) increased, and the proportion of patients who received topical non‐steroidal anti‐inflammatory drugs (12.0%‐3.1%) decreased. Annual costs for medication associated with AD per person/visit increased between 2005 and 2017; however, the ratio of medication to total cost did not. Conclusions The results of this analysis show that Japanese patients used increasingly potent treatments for AD, and overall AD‐related medication costs increased between 2005 and 2017